Literature DB >> 18037117

Pyoderma gangrenosum: an update.

Jeffrey P Callen1, J Mark Jackson.   

Abstract

Pyoderma gangrenosum (PG) can be differentiated into classic and atypical forms. The classic form is characterized by ulcers and the atypical form by deep erosions with bullous blue-gray margins. Pathergy, the development of cutaneous lesions at sites of trauma, is a common feature of both forms of PG. Approximately 50% of patients who have PG have underlying systemic diseases, most commonly inflammatory bowel disease, myeloproliferative disorders, and various forms of inflammatory arthritis. The diagnosis of PG is one of exclusion. The management of this disorder begins with treatment of any underlying disease and local or systemic glucocorticoids or immunomodulating therapies.

Entities:  

Mesh:

Year:  2007        PMID: 18037117     DOI: 10.1016/j.rdc.2007.07.016

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  29 in total

1.  [Surgical management of Pyoderma gangrenosum].

Authors:  I Sick; B Trautner; T Ruzicka
Journal:  Hautarzt       Date:  2012-07       Impact factor: 0.751

2.  Pyostomatitis vegetans: cellular immune profile and expression of IL-6, IL-8 and TNF-alpha.

Authors:  Giuseppe Ficarra; Gianna Baroni; Daniela Massi
Journal:  Head Neck Pathol       Date:  2009-11-14

3.  Successful treatment of pyoderma gangrenosum associated with juvenile idiopathic arthritis with a combination of topical tacrolimus and oral prednisolone.

Authors:  Pradeep Kumar Shenoy Chandrasekhara; Nambiar Veettil Jayachandran; Joe Thomas; Sumeet Agrawal; Gumdal Narsimulu
Journal:  Clin Rheumatol       Date:  2009-02-03       Impact factor: 2.980

4.  Development of pyoderma gangrenosum during therapy with infliximab.

Authors:  Natalia Jaimes-López; Verónica Molina; Juan E Arroyave; Luz A Vasquez; Ana C Ruiz; Rodrigo Castaño; Mario H Ruiz
Journal:  J Dermatol Case Rep       Date:  2009-08-24

5.  A surgeon's nightmare: pyoderma gangrenosum with pathergy effect mimicking necrotising fasciitis.

Authors:  Amanda Mun Yee Slocum
Journal:  BMJ Case Rep       Date:  2017-12-20

6.  Characteristics and treatment of pyoderma gangrenosum in inflammatory bowel disease.

Authors:  F Argüelles-Arias; L Castro-Laria; T Lobatón; M Aguas-Peris; M Rojas-Feria; M Barreiro-de Acosta; P Soto-Escribano; M Calvo-Moya; D Ginard-Vicens; M Chaparro-Sánchez; M Hernández-Durán; B Castro-Senosiain; A Fernández-Villaverde; V García-Sánchez; E Domínguez-Muñoz; A Caunedo-Álvarez; J M Herrerías-Gutiérrez
Journal:  Dig Dis Sci       Date:  2013-07-05       Impact factor: 3.199

7.  Pyoderma gangrenosum - a guide to diagnosis and management .

Authors:  Christina George; Florence Deroide; Malcolm Rustin
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

8.  Pyoderma gangrenosum.

Authors:  Sanwar Agrawal; Bharat Singhania
Journal:  BMJ Case Rep       Date:  2010-10-28

9.  Pyoderma gangrenosum: variation in clinical presentation at different ages.

Authors:  Banavasi S Girisha; Manjunath M Shenoy; Michelle Mathias; Vijaya Shenoy
Journal:  Indian J Dermatol       Date:  2011-05       Impact factor: 1.494

10.  Skin manifestations of inflammatory bowel disease.

Authors:  Brian L Huang; Stephanie Chandra; David Quan Shih
Journal:  Front Physiol       Date:  2012-02-06       Impact factor: 4.566

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.